What is the recommended management of hyperkalemia?

Treatment of Hyperkalemia

For acute hyperkalemia with ECG changes or severe elevation, immediately administer IV calcium gluconate (10 mL of 10%) to stabilize cardiac membranes, followed by insulin/glucose (10 units + 50 mL dextrose) and nebulized salbutamol (20 mg in 4 mL) to shift potassium intracellularly, while for chronic hyperkalemia, use newer potassium binders (patiromer or sodium zirconium cyclosilicate) to enable continuation of life-saving RAAS inhibitor therapy. 1

Acute Hyperkalemia Management

Immediate Cardiac Stabilization

• IV calcium gluconate (10 mL of 10%) acts within 1-3 minutes to reduce membrane excitation in cardiac tissue and minimize arrhythmia risk, though it does not lower total body potassium 1
• If no effect within 5-10 minutes, repeat the calcium dose 1
• Monitor ECG continuously for peaked T waves and prolonged QRS complexes, though ECG findings are highly variable and not as sensitive as laboratory testing 1

Intracellular Potassium Shift (30-60 minutes onset)

• IV insulin (10 units) plus glucose (50 mL dextrose) redistributes potassium into cells but does not eliminate total body potassium 1
• Nebulized salbutamol (20 mg in 4 mL) provides additional intracellular shift with short duration (2-4 hours) 1
• IV sodium bicarbonate only in patients with concurrent metabolic acidosis to promote urinary potassium excretion 1

Potassium Elimination

• Loop diuretics in hypervolemic, non-oliguric patients to enhance renal potassium excretion 1
• Hemodialysis for resistant acute hyperkalemia, oliguria, or end-stage renal disease 1
• Consider potassium binders early as insulin, salbutamol, and bicarbonate provide only temporary benefit (1-4 hours) with rebound hyperkalemia occurring after 2 hours 1

Chronic Hyperkalemia Management

Newer Potassium Binders (First-Line)

Sodium Zirconium Cyclosilicate (SZC):

• Fastest onset at 1 hour, highly selective for potassium 1
• Acute correction: 10 g three times daily for 48 hours 1
• Maintenance: 5-15 g once daily titrated to maintain potassium 3.5-5.0 mEq/L 1
• Acts in both small and large intestines 1
• Most common adverse effects: constipation, diarrhea, nausea, mild-to-moderate edema 1
• Contains 400 mg sodium per 5 g dose 1

Patiromer:

• Onset at 7 hours, exchanges calcium for potassium in colon 1
• Dosing: Start 8.4 g once daily, titrate up to 25.2 g once daily 1
• Must separate from other oral medications by 3+ hours due to binding potential 1
• Most common adverse effects: gastrointestinal disorders, hypomagnesemia, rare hypercalcemia 1
• Contains 1.6 g calcium per 8.4 g dose 1

Avoid Sodium Polystyrene Sulfonate (SPS)

• Associated with intestinal ischemia, colonic necrosis, and 33% mortality rate 1
• Inconsistent short-term efficacy with variable onset (hours to days) 1
• Lacks clinical studies supporting long-term use 1
• Nonselective binding causes hypocalcemia and hypomagnesemia 1

Critical RAAS Inhibitor Management

Do Not Discontinue RAAS Inhibitors for Hyperkalemia

• Discontinuation of RAAS inhibitors increases mortality and major adverse cardiovascular events compared to continuation, even with declining kidney function 1
• Approximately 50% of patients on RAAS inhibitors experience recurrent hyperkalemia within 1 year 1, 2
• Maximum RAAS inhibitor therapy should be maintained when indicated 1

Algorithm for RAAS Inhibitor Continuation

• If hyperkalemia develops: Treat the hyperkalemia first with potassium binders rather than reducing RAAS inhibitor dose 1, 3
• After acute resolution: Reinitiate RAAS inhibitors if discontinued, with potassium reassessment within 1 week 1
• Identify and remove other hyperkalemia risk factors: NSAIDs, potassium supplements, high-potassium diet 1
• Use newer potassium binders (patiromer or SZC) to enable optimization of RAAS inhibitor therapy 1

Monitoring Strategy

Frequency Based on Risk

• Measure potassium within 1 week of starting RAAS inhibitors or dose escalation 1
• More frequent monitoring in patients with CKD, diabetes, heart failure, or history of hyperkalemia 1
• Serum potassium ≥5.5 mEq/L is widely accepted as hyperkalemia threshold, though adverse outcomes occur even at high-normal levels (>5.0 mEq/L) in heart failure and CKD patients 1

Laboratory Considerations

• Plasma potassium is 0.1-0.4 mEq/L lower than serum due to platelet release during coagulation 1
• Rule out pseudohyperkalemia from fist clenching, hemolysis, or slow specimen processing before treatment 1

Common Pitfalls

• Rebound hyperkalemia occurs 2 hours after acute treatments that only shift potassium intracellularly; initiate potassium binders early 1
• Glucose must be administered with insulin to prevent hypoglycemia 1
• Diuretics carry risks of volume contraction and renal function deterioration 4
• Focus on clinical impact and rapid fluctuations rather than rigid potassium thresholds when deciding treatment intensity 1
• Patiromer-induced hypercalcemia is underreported; monitor calcium levels 1